Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in Cytopenia Patients
Recruiting
Observational Study
Cytopenia
MDS
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,500 (estimated)
- Sponsor
- Weizmann Institute of Science · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This observational, multi-center study aims to collect data in order to develop a novel, minimally invasive diagnostic tool for MDS based on peripheral blood profiling of circulating hematopoietic stem and progenitor cells (cHSPCs) using single-cell RNA sequencing and DNA sequencing.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Patients aged 18 and up with suspected/confirmed MDS cases referred to BM evaluation either for diagnosis or risk assessment due to cytopenia
2. Platelets \< 150 × 10E9/L or
3. Absolute neutrophil count \< 1.8 × 10E9/L or
4. Hemoglobin (Hgb) \< 13 g/dL (males) and \< 12 g/dL …
Contacts